Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 11:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension, Smoking Cessation
Interventions: Data, Panel Management Support, Education; Other
Lead sponsor: VA New York Harbor Healthcare System; Federal
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Polycystic Ovarian Syndrome, Idiopathic Intracranial Hypertension
Interventions: Not listed
Lead sponsor: National Aeronautics and Space Administration; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: High Blood Pressure
Interventions: Produce Prescription for Healthy Blood Pressure (PRx-BP) program; Behavioral
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
Interventions: Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program; Procedure · Drug · Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypertension, Pregnancy-Induced
Interventions: furosemide, labetalol; Drug
Lead sponsor: Wright State University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Medication Adherence, High Blood Pressure, Diabetes
Interventions: Medication Adherence Partner, Electronic pill bottle; Behavioral · Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Elevated Intraocular Pressure (IOP)
Interventions: Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug; Combination Product
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Essential Hypertension
Interventions: perindopril erbumine; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia, Pulmonary; Hypertension
Interventions: Fetal Tracheal Occlusion; Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertension, Hemodialysis
Interventions: Digoxin immune fab, Placebo; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Hypertension
Interventions: olmesartan medoxomil, Placebo, losartan potassium; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 941 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 20
States / cities: Mesa, Arizona • Phoenix, Arizona • Harbor City, California + 17 more

Conditions: Ocular Hypertension, Glaucoma
Interventions: AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 19 Years to 99 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2, bimatoprost 6 µg generation 2, bimatoprost 15 µg generation 1, bimatoprost 10 µg generation 1, bimatoprost 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 36
States / cities: Artesia, California • La Jolla, California • Los Angeles, California + 31 more

Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Prospective study assessments; Other
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 70
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more

Conditions: Hypertension, Diabetes Mellitus, Type 2
Interventions: Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function; Drug · Device · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 35 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma, Chronic Angle Closure Glaucoma
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes, Stroke, Obesity
Interventions: Not listed
Lead sponsor: Children's & Women's Health Centre of British Columbia; Other
Eligibility: Not listed
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 4
States / cities: New Haven, Connecticut • Louisville, Kentucky • Camden, New Jersey + 1 more

Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 20 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Healthy, Pre Hypertension
Interventions: Exercise capacity VO2 max determination, Standardized meals, Exercise challenge, Metoprolol Succinate ER; Other · Dietary Supplement · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 40 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypertensive Urgency
Interventions: nicardipine intravenous, Labetalol; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Cleveland, Ohio • Houston, Texas

Conditions: Racial Disparities, Blood Pressure, Cardiovascular Risk Factor, Renal Function
Interventions: MitoQ; Dietary Supplement
Lead sponsor: Auburn University; Other
Eligibility: 19 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Pre Eclampsia
Interventions: Sphygmo; Device
Lead sponsor: William Marsh Rice University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension
Interventions: Valsartan and hydrochlorothiazide (HCTZ) - monotherapy, Valsartan and amlodipine, Usual care, Valsartan, Valsartan and hydrochlorothiazide (HCTZ) - combination arm; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,337 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Glaucoma, Macular Degeneration, Glaucoma Suspect, Optic Neuropathy, Retinal Degeneration, Visual Pathway Disorder
Interventions: Visual Performance tests, Brain-computer interface; Diagnostic Test · Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 90 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Program for Research on the Outcomes of VA Education

Astronaut Vision Issues in a Ground Analog Population: Polycystic Ovary Syndrome

Produce Prescription for Healthy Blood Pressure

Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

Postpartum Management of Gestational Hypertensive Disorders Using Furosemide

Social Forces to Improve Statin Adherence (Study A)

Safety and Intraocular Lowering Effect of Delivery of Travoprost Evolute® in Subjects With Elevated Intraocular Pressure

Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions

Feto-Endoscopic Tracheal Occlusion (FETO) for Severe Congenital Diaphragmatic Hernia

Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease

Olmesartan Comparison to Losartan in Hypertensive Subjects

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

Advanced Glaucoma Progression Study

Testing the Developmental Origins Hypothesis

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Race, Natriuretic Peptides and Physiological Perturbations

Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department

The Influence of Mitochondrial-Derived Reactive Oxygen Species on Racial Disparities in Neurovascular Function

Accuracy Assessment of an Automatic Blood Pressure Measurement Device in Pregnant Women

Valsartan Intensified Primary Care Reduction of Blood Pressure Study

BCI and Evaluation of Visual and Task Performance in Subjects With Eye Diseases